Lantus for Prediabetes: Evidence, Dosing, and What Guidelines Actually Say

What Is Prediabetes and Who Gets Treated?

Prediabetes affects roughly 98 million American adults, according to CDC estimates, though most never receive pharmacotherapy [1]. The diagnostic thresholds are a fasting plasma glucose of 100 to 125 mg/dL, an A1c of 5.7% to 6.4%, or impaired glucose tolerance on a 2-hour oral glucose tolerance test.

Lifestyle modification remains the strongest evidence-based intervention. The Diabetes Prevention Program (DPP, N=3,234) showed that structured diet and exercise reduced diabetes incidence by 58% over 2.8 years, compared with 31% for metformin [2]. These results have shaped guidelines for over two decades. The ADA Standards of Care state: "Metformin therapy for prevention of type 2 diabetes should be considered in those with prediabetes, especially those with BMI ≥35 kg/m², those aged <60 years, and women with prior gestational diabetes mellitus" [3]. No guideline body currently recommends insulin for prediabetes prevention.

So where does Lantus fit? The short answer: it sits in a gray zone between promising trial data and practical clinical limitations that keep it off every major guideline's recommendation list.

What the ORIGIN Trial Found

The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is the only large randomized study testing basal insulin in a population that included people with prediabetes [4]. Published in the New England Journal of Medicine in 2012, ORIGIN enrolled 12,537 participants aged 50 and older who had cardiovascular risk factors plus either impaired fasting glucose, impaired glucose tolerance, or recently diagnosed type 2 diabetes.

Participants were randomized to insulin glargine (titrated to a fasting glucose target of ≤95 mg/dL) or standard care. Median follow-up was 6.2 years. The primary cardiovascular composite endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) was neutral, with a hazard ratio of 1.02 (95% CI 0.94 to 1.11) [4]. That finding was reassuring: early basal insulin did not increase cardiac events.

The glucose-related outcomes told a different story. Among participants who entered the trial without established diabetes (the IFG and IGT subgroups, roughly 18% of the cohort), glargine reduced progression to new-onset type 2 diabetes. The hazard ratio was approximately 0.80, a 20% relative risk reduction [4]. This result suggested that stabilizing fasting glucose with a small daily dose of basal insulin could slow beta-cell decline.

There was a catch. The ORIGIN and Legacy Effects (ORIGINALE) extension study found that once glargine was discontinued, the diabetes prevention advantage faded within three years [5]. That stands in contrast to lifestyle intervention, which maintained a 27% risk reduction at 15 years of follow-up in the DPP Outcomes Study [6].

Why Lantus Is Not FDA-Approved for Prediabetes

The FDA approves drugs for specific labeled indications based on submitted data packages. Sanofi has never filed a supplemental New Drug Application seeking a prediabetes indication for insulin glargine [7]. Three reasons explain why.

First, the regulatory bar for a diabetes prevention claim is high. The FDA expects durable benefit after drug discontinuation, and ORIGIN did not demonstrate that. Second, the commercial logic is weak. Glargine lost patent exclusivity in 2015, and biosimilars (Semglee, Rezvoglar) have compressed margins. Filing a new indication costs tens of millions in regulatory fees and post-marketing commitments. Third, insulin carries a hypoglycemia burden that makes risk-benefit calculations difficult in a population whose glucose is only mildly elevated.

The prescribing information for Lantus specifies its approved use as "the treatment of adults and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus to improve glycemic control" [7]. Prediabetes is not mentioned. Any use of glargine for prediabetes is, by definition, off-label.

Off-label does not mean unsupported. Physicians prescribe medications off-label when published evidence supports the use and the clinical situation warrants it. But insurance payers, cost, and risk profile all push against routine off-label glargine for prediabetes.

Dosing Used in the ORIGIN Trial

No FDA-approved dosing for prediabetes exists, so the ORIGIN protocol provides the only large-scale reference point. Trial participants started at 2 units of insulin glargine per day, injected subcutaneously at bedtime [4]. They self-titrated upward by 1 unit every few days until fasting blood glucose reached ≤95 mg/dL. The median dose at study end was approximately 0.31 units/kg/day.

That dose is low. Compare it to typical type 2 diabetes initiation at 10 units/day (roughly 0.1 to 0.2 units/kg) or eventual maintenance doses that often exceed 0.5 units/kg [7]. ORIGIN participants with prediabetes had less insulin resistance than those with established diabetes, so they needed less exogenous insulin to reach target.

Self-titration requires regular fasting glucose monitoring. In the trial, participants checked fasting capillary glucose at least three times per week. A clinician considering off-label glargine for prediabetes would likely follow a similar protocol: start very low (2 to 4 units), titrate by 1 to 2 units every three to seven days, and target a fasting glucose between 80 and 95 mg/dL while watching for hypoglycemia.

Side Effects That Matter for Prediabetes Patients

People with prediabetes have, by definition, mild hyperglycemia. That narrow margin makes side effects that are tolerable in type 2 diabetes harder to justify here.

Hypoglycemia. ORIGIN reported severe hypoglycemia (requiring third-party assistance) at a rate of 1.00 event per 100 person-years in the glargine group versus 0.31 in the standard care group [4]. Non-severe hypoglycemia (self-treated episodes with glucose <54 mg/dL) was more common still. For a patient whose baseline glucose is 110 mg/dL, driving fasting glucose below 95 mg/dL leaves little room before clinically significant hypoglycemia.

Weight gain. Insulin is an anabolic hormone. Glargine-treated participants gained approximately 1.6 kg more than the standard care group over 6.2 years [4]. That is modest by insulin standards, but in prediabetes, where weight loss is itself therapeutic, any upward pressure on body weight runs counter to the primary treatment goal.

Injection burden. Daily subcutaneous injection introduces a compliance and quality-of-life cost. The DPP established that oral metformin (500 to 850 mg twice daily) produces comparable diabetes risk reduction without injections, hypoglycemia, or weight gain [2]. Dr. David Nathan, chair of the DPP Research Group, noted that "lifestyle intervention was significantly more effective than metformin" and that both were "clearly superior to placebo in reducing the incidence of diabetes" [2]. Insulin was not tested in the DPP.

Cancer signal. ORIGIN prospectively tracked cancer incidence and found no increased risk with glargine (HR 1.00 to 95% CI 0.88 to 1.13), addressing a concern raised by earlier observational studies [4].

How Lantus Compares to Metformin for Diabetes Prevention

The comparison is not direct, because no trial randomized patients to glargine versus metformin for prediabetes prevention. But the available data allow indirect comparison.

The DPP assigned 3,234 participants with impaired glucose tolerance and fasting glucose of 95 to 125 mg/dL to lifestyle, metformin 850 mg twice daily, or placebo [2]. Over 2.8 years, lifestyle reduced diabetes incidence by 58% (95% CI 48% to 66%), and metformin reduced it by 31% (95% CI 17% to 43%). Extended follow-up at 15 years in the DPP Outcomes Study confirmed durable benefit: lifestyle still showed a 27% reduction, and metformin maintained an 18% reduction [6].

ORIGIN's glargine arm achieved roughly a 20% reduction in new-onset diabetes, but only during active treatment [4][5]. After discontinuation, rates converged. A clinician weighing these two drugs for a prediabetes patient faces a clear asymmetry:

| Factor | Metformin | Insulin Glargine | |---|---|---| | Diabetes risk reduction | 31% (DPP) | ~20% (ORIGIN) | | Durability after stopping | Partial (18% at 15 yr) | None within 3 yr | | Hypoglycemia risk | Negligible | 3-fold increase | | Weight effect | Neutral to slight loss | ~1.6 kg gain | | Route | Oral | Subcutaneous injection | | Cost (generic/biosimilar) | ~$4 to $10/month | ~$30 to $90/month | | FDA prediabetes indication | No (but guideline-endorsed) | No |

The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity for diabetes prevention recommends metformin or GLP-1 receptor agonists for high-risk prediabetes but does not include insulin [8]. The American Association of Clinical Endocrinology (AACE) takes a similar position, stating that "pharmacologic agents such as metformin may be considered" while listing lifestyle as first-line [9].

Insurance and Cost Barriers

Getting an insurer to cover Lantus for prediabetes is difficult. The claim would carry an ICD-10 code of R73.03 (prediabetes) rather than E11.x (type 2 diabetes). Because glargine has no FDA-approved indication for prediabetes, most formulary policies treat this as a non-covered, off-label use.

The list price of brand-name Lantus (Sanofi) is approximately $350 per box of five 3 mL pens. At low prediabetes-range dosing (5 to 15 units/day), a box could last one to three months. Biosimilar insulin glargine products (Semglee by Organon, Rezvoglar by Eli Lilly) cost 50% to 65% less at retail, and interchangeable biosimilars can be substituted at the pharmacy without a new prescription in most states [10].

Even with biosimilar pricing, the cost-per-quality-adjusted-life-year for insulin in prediabetes is unfavorable compared with metformin (available at $4/month through many pharmacy discount programs) or structured lifestyle intervention (which the CDC's National Diabetes Prevention Program delivers at no out-of-pocket cost through many insurers) [1][3].

A patient whose physician prescribes off-label glargine should expect to file a prior authorization, provide supporting documentation from the ORIGIN trial, and potentially appeal an initial denial. Success rates for such appeals are not published, but endocrinologists who treat high-risk prediabetes report that approvals are uncommon without a concurrent type 2 diabetes diagnosis.

When a Clinician Might Consider Off-Label Glargine

Given the evidence gaps and practical barriers, off-label glargine for prediabetes is reserved for narrow clinical scenarios. A physician might consider it when all of the following apply: the patient has failed structured lifestyle intervention over 6 to 12 months, metformin is contraindicated or not tolerated (true contraindications include eGFR <30 mL/min/1.73 m² and certain drug interactions), GLP-1 receptor agonists are unavailable or unaffordable, and fasting glucose is trending toward the diabetic range (repeatedly 120 to 125 mg/dL or A1c 6.3% to 6.4%) [3][9].

This is a last-line scenario. Dr. Hertzel Gerstein, the lead investigator of the ORIGIN trial, wrote that "early use of basal insulin glargine had a neutral effect on cardiovascular outcomes and cancers" but did not recommend it as standard prediabetes therapy, noting that the study was designed primarily as a cardiovascular safety trial rather than a diabetes prevention study [4].

Clinicians who do prescribe off-label glargine in this setting should document the clinical rationale, obtain informed consent that covers the off-label nature and hypoglycemia risk, and monitor fasting glucose at least weekly during titration.

What Current Guidelines Recommend for Prediabetes

The 2024 ADA Standards of Care recommend a structured lifestyle program (targeting 7% weight loss and 150 minutes/week of moderate physical activity) as first-line therapy for all patients with prediabetes [3]. Pharmacotherapy with metformin is a secondary option for patients at highest risk: those with BMI ≥35 kg/m², age <60, rising A1c despite lifestyle changes, or a history of gestational diabetes.

GLP-1 receptor agonists have entered the conversation as a third pharmacologic option. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks in the STEP 1 trial (N=1,961) [11], and weight loss of that magnitude substantially lowers diabetes risk. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease [12]. Neither trial specifically enrolled a prediabetes-only population, but the overlap is large.

Insulin does not appear on any guideline's recommended pharmacotherapy list for prediabetes. The evidence from ORIGIN is acknowledged in review articles and meta-analyses, but the lack of durable benefit, the hypoglycemia burden, and the weight gain profile keep it out of recommended algorithms.

Patients with prediabetes who are considering Lantus should discuss the full range of evidence-based options with their physician, starting with lifestyle modification and moving to metformin or GLP-1 receptor agonists before considering basal insulin.